Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.

Spurgeon SE, Sharma K, Claxton DF, Ehmann C, Pu J, Shimko S, Stewart A, Subbiah N, Palmbach G, LeBlanc F, Latour E, Chen Y, Mori M, Hasanali Z, Epner EM.

Br J Haematol. 2019 Jun 9. doi: 10.1111/bjh.16008. [Epub ahead of print]

PMID:
31177537
2.

PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabick JJ, Wang HG, Abraham T, El-Deiry WS, Brodsky RA, J Hohl R, Pu JJ.

Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.

3.

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.

Hasanali ZS, Saroya BS, Stuart A, Shimko S, Evans J, Vinod Shah M, Sharma K, Leshchenko VV, Parekh S, Loughran TP Jr, Epner EM.

Sci Transl Med. 2015 Jun 24;7(293):293ra102. doi: 10.1126/scitranslmed.aaa5079.

4.

Current approaches to epigenetic therapy for the treatment of mantle cell lymphoma.

Ghai V, Sharma K, Abbi KK, Shimko S, Epner EM.

Adv Exp Med Biol. 2013;779:257-66. doi: 10.1007/978-1-4614-6176-0_11. Review.

PMID:
23288643

Supplemental Content

Loading ...
Support Center